Rogaine Rx-to-OTC switch: Upjohn's NDA for switch of minoxidil from prescription to OTC status as a hair regrowth treatment for androgenetic alopecia scheduled for consideration by FDA's Nonprescription Drugs and Dermatologic Drugs Advisory Committees on Nov. 17. The meeting will be held beginning at 8 a.m. in conference rooms D & E of FDA's Parklawn Building...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights